| 发明名称 | Synergistic antiviral compositions comprising a viral attachment inhibitor, integration inhibitor, and proviral transcription inhibitor | ||
| 摘要 | Compounds, compositions and methods for the treatment of HIV/HSP/HPV, in particular, compositions and methods for a 3 part combination therapy for HIV/HSV/HPV, comprising a viral attachment inhibitor, a viral sequence integration inhibitor, and a proviral transcription inhibitor. The therapy is advantageous for the treatment of HIV infection, and is also effective for HSV and HPV infection. Also disclosed are novel viral attachment inhibitors and methods of use. | ||
| 申请公布号 | US9005889(B2) | 申请公布日期 | 2015.04.14 |
| 申请号 | US200812523513 | 申请日期 | 2008.01.16 |
| 申请人 | The Johns Hopkins University | 发明人 | Huang Ru Chih C.;Abd-Elazem Ibrahim S. |
| 分类号 | C12Q1/70;A61K39/21;A61K45/06;A61K31/704 | 主分类号 | C12Q1/70 |
| 代理机构 | Johns Hopkins Technology Transfer | 代理人 | Johns Hopkins Technology Transfer |
| 主权项 | 1. A pharmaceutical composition comprising a viral attachment inhibitor, a viral sequence integration inhibitor, and a proviral transcription inhibitor, in synergistic amounts effective to treat the symptoms of or inhibit the course of HIV infection, and a pharmaceutically acceptable carrier, wherein the triterpenoid saponin or derivative thereof is selected from the group consisting of arganine C (Rev. 1), Tieghemelin (Gen.1), acetylated arganine C or acetylated Tieghemelin, wherein the viral sequence integration inhibitor is lithospermic acid (M522) or lithospermic acid B (M532), and wherein the proviral transcription inhibitor is a nontoxic water-soluble derivative of NDGA selected from the group consisting of M4N, G4N, P4N and Ma1.4. | ||
| 地址 | Baltimore MD US | ||